CRISPR BY DESIGN
DEAD

Serial Number

90596751

Owner

Scribe Therapeutics Inc.

Attorney

John Paul Oleksiuk

Filing Date

Mar 23, 2021

Add to watchlist:

No watchlists yet
View on USPTO

CRISPR BY DESIGN Trademark

Serial Number: 90596751

CRISPR BY DESIGN is a trademark filed by Scribe Therapeutics Inc. on March 23, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

Scribe Therapeutics Inc. (10 trademarks)

Alameda, CA 94501

Entity Type: 03

Trademark Details

Filing Date

March 23, 2021

Registration Date

Not Registered

Published for Opposition

June 21, 2022

Goods & Services

Pharmaceutical and biological preparations based on genetic engineering and gene therapy for use in diagnosis, prevention, and treatment of diseases in human therapeuticsin the nature of diseases caused by genetic mutations or for which gene modification would ameliorate or cure the disease or disorder; Gene therapy products, namely, biological preparations based on engineered cells for medical use for the treatment of diseases caused by genetic mutations or for which gene modification would ameliorate or cure the disease or disorder related to immuno-oncology, degenerative disorders, traumatic injury, enzyme replacement therapy, and immunology; Pharmaceutical and biological preparations based on gene, genome, and cellular editing, modulation, and modification for use in human therapeutics in the nature of diseases caused by genetic mutations or for which gene modification would ameliorate or cure the disease or disorder; Pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders, namely, neurological disorders, Huntington's disease, amyotrophic lateral sclerosis (ALS), front temporal dementia, pain, Alzheimer's, Parkinson's, ataxia, autism, epilepsy, pain, and also cardiovascular, peripheral nervous system, cancer, endocrine, gastrointestinal, renal, genetic immunological, hepatic, infectious, inflammatory, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, respiratory, urogenital, urological, hematologic and viral or bacterial diseases and disorders

Molecular diagnostic testing, monitoring and reporting services for medical purposes and medical research purposes; Medical diagnostic testing services in the field of human disease and human medical conditions

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Sep 22, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Sep 22, 2025 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 29, 2025 EXRA
SOU EXTENSION 5 GRANTED
Jan 28, 2025 EX5G
SOU EXTENSION 5 FILED
Jan 22, 2025 EXT5
SOU TEAS EXTENSION RECEIVED
Jan 22, 2025 EEXT
CORRECTED NOA E-MAILED
Dec 16, 2024 NOAC
DIVISIONAL PROCESSING COMPLETE
Dec 16, 2024 DPCC
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 16, 2024 EXRA
SOU EXTENSION 4 GRANTED
Dec 16, 2024 EX4G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Nov 22, 2024 AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Nov 18, 2024 AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Oct 23, 2024 AITU
DIVISIONAL REQUEST RECEIVED
Aug 19, 2024 DRRR
TEAS REQUEST TO DIVIDE RECEIVED
Aug 19, 2024 ERTD
SOU EXTENSION 4 FILED
Aug 14, 2024 EXT4
SOU TEAS EXTENSION RECEIVED
Aug 14, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 9, 2024 EXRA
SOU EXTENSION 3 GRANTED
Feb 8, 2024 EX3G
SOU EXTENSION 3 FILED
Feb 8, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
Feb 8, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 12, 2023 EXRA
SOU EXTENSION 2 GRANTED
Aug 10, 2023 EX2G
SOU EXTENSION 2 FILED
Aug 10, 2023 EXT2
SOU TEAS EXTENSION RECEIVED
Aug 10, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 10, 2023 EXRA
SOU EXTENSION 1 GRANTED
Feb 8, 2023 EX1G
SOU EXTENSION 1 FILED
Feb 8, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Feb 8, 2023 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Aug 16, 2022 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 21, 2022 NPUB
PUBLISHED FOR OPPOSITION
Jun 21, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 1, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 19, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 26, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 26, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 26, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 28, 2021 GNRN
NON-FINAL ACTION E-MAILED
Oct 28, 2021 GNRT
NON-FINAL ACTION WRITTEN
Oct 28, 2021 CNRT
ASSIGNED TO EXAMINER
Oct 27, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 28, 2021 NWOS
NEW APPLICATION ENTERED
Mar 26, 2021 NWAP